ValuEngine Downgrades MiMedx Group (MDXG) to Sell
ValuEngine lowered shares of MiMedx Group (NASDAQ:MDXG) from a hold rating to a sell rating in a research report report published on Thursday morning.
MDXG has been the subject of several other reports. BidaskClub lowered MiMedx Group from a hold rating to a sell rating in a research report on Wednesday, February 28th. Craig Hallum reiterated a buy rating on shares of MiMedx Group in a research report on Tuesday, February 27th. Lake Street Capital lowered MiMedx Group from a buy rating to a hold rating and set a $9.00 price objective for the company. in a research report on Friday, February 23rd. Needham & Company LLC lowered MiMedx Group from a strong-buy rating to a hold rating in a research report on Tuesday, February 20th. Finally, Zacks Investment Research lowered MiMedx Group from a hold rating to a sell rating in a research report on Friday, December 8th. Four analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. MiMedx Group presently has an average rating of Hold and a consensus price target of $14.75.
MiMedx Group (NASDAQ MDXG) opened at $7.59 on Thursday. The stock has a market capitalization of $842.76, a PE ratio of 24.48 and a beta of 1.65. MiMedx Group has a 12-month low of $6.05 and a 12-month high of $18.25.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in MiMedx Group in the 3rd quarter valued at approximately $119,000. BlueCrest Capital Management Ltd bought a new stake in MiMedx Group in the 4th quarter valued at approximately $126,000. PVG Asset Management Corp bought a new stake in MiMedx Group in the 3rd quarter valued at approximately $127,000. Ameritas Investment Partners Inc. lifted its stake in MiMedx Group by 7.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 8,619 shares of the medical equipment provider’s stock valued at $129,000 after acquiring an additional 600 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. lifted its stake in MiMedx Group by 6,262.5% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,725 shares of the medical equipment provider’s stock valued at $151,000 after acquiring an additional 12,525 shares in the last quarter. Hedge funds and other institutional investors own 78.86% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/valuengine-downgrades-mimedx-group-mdxg-to-sell/1909093.html.
About MiMedx Group
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.